118 related articles for article (PubMed ID: 14980648)
21. Matrix metalloproteinase proteomics: substrates, targets, and therapy.
Morrison CJ; Butler GS; Rodríguez D; Overall CM
Curr Opin Cell Biol; 2009 Oct; 21(5):645-53. PubMed ID: 19616423
[TBL] [Abstract][Full Text] [Related]
22. Linear and nonlinear QSAR study of N-hydroxy-2-[(phenylsulfonyl)amino]acetamide derivatives as matrix metalloproteinase inhibitors.
Fernández M; Caballero J; Tundidor-Camba A
Bioorg Med Chem; 2006 Jun; 14(12):4137-50. PubMed ID: 16504515
[TBL] [Abstract][Full Text] [Related]
23. 1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.
Zhang YM; Fan X; Chakaravarty D; Xiang B; Scannevin RH; Huang Z; Ma J; Burke SL; Karnachi P; Rhodes KJ; Jackson PF
Bioorg Med Chem Lett; 2008 Jan; 18(1):409-13. PubMed ID: 17981034
[TBL] [Abstract][Full Text] [Related]
24. Design and synthesis of an orally active matrix metalloproteinase inhibitor.
Yamamoto S; Nakatani S; Ikura M; Sugiura T; Nishita Y; Itadani S; Ogawa K; Ohno H; Takahashi K; Nakai H; Toda M
Bioorg Med Chem; 2006 Sep; 14(18):6383-403. PubMed ID: 16765051
[TBL] [Abstract][Full Text] [Related]
25. QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.
Fernández M; Caballero J
Bioorg Med Chem; 2007 Sep; 15(18):6298-310. PubMed ID: 17590339
[TBL] [Abstract][Full Text] [Related]
26. Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
Le Diguarher T; Chollet AM; Bertrand M; Hennig P; Raimbaud E; Sabatini M; Guilbaud N; Pierré A; Tucker GC; Casara P
J Med Chem; 2003 Aug; 46(18):3840-52. PubMed ID: 12930146
[TBL] [Abstract][Full Text] [Related]
27. In silico study of MMP inhibition.
Rouffet M; Denhez C; Bourguet E; Bohr F; Guillaume D
Org Biomol Chem; 2009 Sep; 7(18):3817-25. PubMed ID: 19707688
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of an inhibitor-tethered resin for detection of active matrix metalloproteinases involved in disease.
Hesek D; Toth M; Krchnak V; Fridman R; Mobashery S
J Org Chem; 2006 Aug; 71(16):5848-54. PubMed ID: 16872162
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.
Nuti E; Panelli L; Casalini F; Avramova SI; Orlandini E; Santamaria S; Nencetti S; Tuccinardi T; Martinelli A; Cercignani G; D'Amelio N; Maiocchi A; Uggeri F; Rossello A
J Med Chem; 2009 Oct; 52(20):6347-61. PubMed ID: 19775099
[TBL] [Abstract][Full Text] [Related]
30. Quantitative structure-activity relationship studies on sulfonamide-based MMP inhibitors.
Patil VM; Gupta SP
Exp Suppl; 2012; 103():177-208. PubMed ID: 22642193
[TBL] [Abstract][Full Text] [Related]
31. Protective effect of matrix metalloproteinase inhibitors against epidermal basement membrane damage: skin equivalents partially mimic photoageing process.
Amano S; Ogura Y; Akutsu N; Matsunaga Y; Kadoya K; Adachi E; Nishiyama T
Br J Dermatol; 2005 Dec; 153 Suppl 2():37-46. PubMed ID: 16280020
[TBL] [Abstract][Full Text] [Related]
32. Quantitative structure-activity relationship studies on zinc-containing metalloproteinase inhibitors.
Gupta SP
Chem Rev; 2007 Jul; 107(7):3042-87. PubMed ID: 17622180
[No Abstract] [Full Text] [Related]
33. Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis.
Janusz MJ; Hookfin EB; Brown KK; Hsieh LC; Heitmeyer SA; Taiwo YO; Natchus MG; Pikul S; Almstead NG; De B; Peng SX; Baker TR; Patel V
Inflamm Res; 2006 Feb; 55(2):60-5. PubMed ID: 16612565
[TBL] [Abstract][Full Text] [Related]
34. A high-affinity carbohydrate-containing inhibitor of matrix metalloproteinases.
Calderone V; Fragai M; Luchinat C; Nativi C; Richichi B; Roelens S
ChemMedChem; 2006 Jun; 1(6):598-601. PubMed ID: 16892399
[No Abstract] [Full Text] [Related]
35. Synthesis of new sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
Cheng XC; Wang Q; Fang H; Tang W; Xu WF
Bioorg Med Chem; 2008 Sep; 16(17):7932-8. PubMed ID: 18718763
[TBL] [Abstract][Full Text] [Related]
36. Snapshots of the reaction mechanism of matrix metalloproteinases.
Bertini I; Calderone V; Fragai M; Luchinat C; Maletta M; Yeo KJ
Angew Chem Int Ed Engl; 2006 Dec; 45(47):7952-5. PubMed ID: 17096442
[No Abstract] [Full Text] [Related]
37. Chymase and matrix metalloproteinase.
Urata H
Hypertens Res; 2007 Jan; 30(1):3-4. PubMed ID: 17460365
[No Abstract] [Full Text] [Related]
38. Synthesis, SAR, and biological evaluation of alpha-sulfonylphosphonic acids as selective matrix metalloproteinase inhibitors.
Rubino MT; Agamennone M; Campestre C; Fracchiolla G; Laghezza A; Loiodice F; Nuti E; Rossello A; Tortorella P
ChemMedChem; 2009 Mar; 4(3):352-62. PubMed ID: 19204958
[TBL] [Abstract][Full Text] [Related]
39. Activity-based matrix metallo-protease enrichment using automated, inhibitor affinity extractions.
Freije JR; Klein T; Ooms JA; Franke JP; Bischoff R
J Proteome Res; 2006 May; 5(5):1186-94. PubMed ID: 16674108
[TBL] [Abstract][Full Text] [Related]
40. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
